PE investment creates ‘strong foundation’ for growth: Clinical Ink CEO

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/Duncan_Andison)
(Image: Getty/Duncan_Andison)
The private equity firm NovaQuest Capital Management is leading a majority recapitalization and growth equity investment in Clinical Ink.

Yesterday, Clinical Ink announced that a majority of its outstanding shares from existing investors have been acquired by NovaQuest Capital Management, L.L.C., a private equity firm which also “provided a substantial infusion of additional growth capital.” 

As part of this, the research institute RTI International has announced a strategic co-investment in Clinical Ink, which also has been provided a flexible credit facility from Silicon Valley Bank.

The deal – financial details of which were not disclosed – provides Clinical Ink with a “strong foundation”​ to ensure it has “the right capital resources to continue growth,”​ the company’s CEO Ed Seguine told us.

The deal is a reflection of Clinical Ink’s technology platform, management team, and “strong business model,” ​Seguine said, ​adding that it validates the company’s “homegrown potential to go and compete head-on with some of the biggest players in this area.”

The NC-based company’s SureSource platform captures eSource, ePRO, and eCOA data and documents for risk-based monitoring.

“We need to create a better clinical trial experience,”​ Seguine said. “We’re focused on using our technology the moment that it matters … during the patient visit.”

Related topics Clinical Development

Related news

Show more

Follow us